Marina Acevedo Zarzar de Melo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Acevedo Zarzar de Melo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Mariana Carvalho Gouveia
Yale University, Department of Medical Oncology, New Haven, CT, USA; Hospital 9 de Julho-Américas Oncologia, Department of Medical Oncology, São Paulo, Brazil; Early Career Editorial Board Member, International Journal of Gynecological Cancer
4 shared publications - Mariana Scaranti
Hospital 9 de Julho - Américas Oncologia, São Paulo, Brazil
3 shared publications - Jorge Sabbaga
Department of Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
2 shared publications - Jéssica Monteiro Vasconcellos
Universidade de Brasília, Hospital Universitário de Brasília (HUB-UnB/Ebserh), Brasília, DF, Brazil; Instituto D'Or de Ensino e Pesquisa (IDOR), Brasília, Brazil
2 shared publications - Leonardo Gomes da Fonseca
Instituto Do Cancer do Estado de São Paulo, Hospital das Clínicas Universidade São Paulo São Paulo Brazil
2 shared publications - Letícia Vecchi Leis
Faculdade de Medicina da Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil; Instituto D'Or de Ensino e Pesquisa (IDOR), São Paulo, Brazil
2 shared publications
Latest Publications
- 16 June 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104813
ASCO Annual Meeting 2026: Key Clinical Trial Updates in Gynecologic Oncology
- 16 June 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104813
ASCO Annual Meeting 2026: Key Clinical Trial Updates in Gynecologic Oncology
- 10 April 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104699
Beyond endocrine therapy: evolving treatment strategies in low-grade serous ovarian carcinoma
- 10 April 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104699
Beyond endocrine therapy: evolving treatment strategies in low-grade serous ovarian carcinoma
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2262-2273
Prognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study
Background: The systemic treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinase inhibitors, such as sorafenib (SOR), to immune checkpoint inhibitor-based combinations (IO). Despite these advances, there is a lack of simple, objective tools to stratify patient prognosis in clinical practice. While several laboratory parameters are known to correlate with outcomes, their combined utility across treatment types remains unclear. We aimed to evaluate the prognostic value of commonly available biomarkers and to develop a simplified score applicable to both SOR- and IO-treated patients. Methods: This retrospective cohort study analyzed patients with advanced or intermediate-stage HCC treated with first-line systemic therapy at a single center in Brazil from 2009 to 2024. Patients were stratified into a SOR cohort and an IO cohort. Baseline variables included demographics and biochemical markers. We assessed the association between survival and three baseline biomarkers: alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio (NLR). A prognostic score was developed in the SOR cohort by assigning one point to each adverse factor: AFP ≥200 ng/mL, ALBI grade 2–3, and NLR ≥3. Overall survival (OS) was estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox regression models. Results: The study included 440 patients in the SOR cohort and 32 in the IO cohort. In the SOR cohort. Most patients in both cohorts were Child-Pugh A, PS 0–1 and hepatitis C was the predominant etiology. AFP ≥200 ng/mL (Pvs. 2–3 points had significantly different OS (HR 2.2; 95% CI: 1.1–4.9; P=0.04). Conclusions: This simplified prognostic score, based on three routine laboratory parameters, stratifies survival outcomes in HCC patients receiving either sorafenib or immunotherapy. While further validation is needed in larger and more diverse populations, this tool may support individualized clinical counseling and risk-adapted trial design.
- 1 October 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2262-2273
Open AccessPrognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study
Background: The systemic treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinase inhibitors, such as sorafenib (SOR), to immune checkpoint inhibitor-based combinations (IO). Despite these advances, there is a lack of simple, objective tools to stratify patient prognosis in clinical practice. While several laboratory parameters are known to correlate with outcomes, their combined utility across treatment types remains unclear. We aimed to evaluate the prognostic value of commonly available biomarkers and to develop a simplified score applicable to both SOR- and IO-treated patients. Methods: This retrospective cohort study analyzed patients with advanced or intermediate-stage HCC treated with first-line systemic therapy at a single center in Brazil from 2009 to 2024. Patients were stratified into a SOR cohort and an IO cohort. Baseline variables included demographics and biochemical markers. We assessed the association between survival and three baseline biomarkers: alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio (NLR). A prognostic score was developed in the SOR cohort by assigning one point to each adverse factor: AFP ≥200 ng/mL, ALBI grade 2–3, and NLR ≥3. Overall survival (OS) was estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox regression models. Results: The study included 440 patients in the SOR cohort and 32 in the IO cohort. In the SOR cohort. Most patients in both cohorts were Child-Pugh A, PS 0–1 and hepatitis C was the predominant etiology. AFP ≥200 ng/mL (Pvs. 2–3 points had significantly different OS (HR 2.2; 95% CI: 1.1–4.9; P=0.04). Conclusions: This simplified prognostic score, based on three routine laboratory parameters, stratifies survival outcomes in HCC patients receiving either sorafenib or immunotherapy. While further validation is needed in larger and more diverse populations, this tool may support individualized clinical counseling and risk-adapted trial design.
- 14 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (5) , 101769
A promising partnership? Exploring cyclin-dependent kinase 4/6 inhibition and hormonal therapy in endometrial cancer
- 14 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (5) , 101769
A promising partnership? Exploring cyclin-dependent kinase 4/6 inhibition and hormonal therapy in endometrial cancer
- 1 February 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 98 (2) , e4-e6
Real-World Comparative Analysis of Liposomal Doxorubicin Versus Paclitaxel as First-Line Therapy for Kaposi Sarcoma
An abstract is unavailable. This article is available as a PDF only.
- 1 February 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 98 (2) , e4-e6
Real-World Comparative Analysis of Liposomal Doxorubicin Versus Paclitaxel as First-Line Therapy for Kaposi Sarcoma
An abstract is unavailable. This article is available as a PDF only.